MediGene AG · LS:A40ESG

MediGene — Q3 2009 Earnings Presentation

11 slides from MediGene's earnings presentation, Nov 13, 2009

  1. Slide 1: Earnings call Q3/2009

    Earnings call Q3/2009 Munich, November 13, 2009 Dr. Frank Mathias, CEO Dr. Thomas Klaue, CFO Dr. Axel Mescheder, CDO & CSO

  2. Slide 2: Forward-looking statements

    This presentation contains forward-looking statements - that is, statements related to future, not past, events. These statements may be identified either orally or in writing by words as "expects", "anticipates", "intents", "plans", "believes", "seeks", "estimates", "will", "may" or words of simila

  3. Slide 3: Overview

    Overview

  4. Slide 4: Important steps made in first nine months (1)

    Important steps made in first nine months (1) ƒ Veregen® : • Start of sales promotion in the USA through partner Nycomed • Positive assessment on market authorization for Veregen® in the first European countries, marketing authorization for Germany granted • Marketing partnership agreements conclude

  5. Slide 5: Important steps made in first nine months (2)

    Important steps made in first nine months (2) ƒ RhuDexTM: • Authorities agree to continuation of clinical development of RhuDexTM ƒ Organisation: • Dr. Frank Mathias appointed new Chief Executive Officer of MediGene • Reorganization initiated: shift of employees and financial resources to clinical d

  6. Slide 6: Financials

    Financials

  7. Slide 7: Financials Q3 2009

    Financials Q3 2009 In T€ Q3 2009 Q3 2008 Change Total revenue 8,579 11,742 -27% Cost of sales -7,321 -6,039 21% Gross profit 1,258 5,703 -78% Operating expenses -7,572 -8,744 -13% EBITDA -6,314 -3,041 108% Loss resulting from spin-off and depreciation -208 -6,577* 97% Operating result -6,522 -9,618

  8. Slide 8: Financials 9M 2009

    Financials 9M 2009 In T€ 9M 2009 9M 2008 Change Total revenue 28,568 25,510 12% Cost of sales -21,850 -16,012 36% Gross profit 6,718 9,498 -29% Operating expenses -19,814 -29,016 -32% EBITDA -13,096 -19,518 -33% Loss resulting from spin-off and depreciation -622 -7,232* -91% Operating result -13,718

  9. Slide 9: Outlook and financial forecast 2009: Product revenues further up, losses narrowed

    Outlook and financial forecast 2009: Product revenues further up, losses narrowed ƒ Sales to increase, therefore total revenue of app. € 40 mio (2008: total revenue € 39.6 mio) ƒ Average monthly cash burn rate for the remaining 3 months 2009 app. € 1.5 mio; possibly additional spending on EndoTAG™-1

  10. Slide 10: Q&A

    Q&A

  11. Slide 11: MediGene AG contact details

    MediGene AG Lochhamer Straße 11 82152 Planegg / Martinsried, Germany Phone: +49 89 85 65 29 00 Fax: +49 89 85 65 29 20 www.medigene.com MediGene Ltd. 57c Milton Park Abingdon, Oxon, OX14 4RX United Kingdom Phone: +44 1235 438600 Fax: +44 1235 438601 MediGene Inc. 10660 Scripps Ranch Blvd., Suite 200

MediGene — Q3 2009 Earnings Presentation on 6ix